Qiagen Overview
- Founded
-
1984
- Status
-
Public
- Employees
-
6,200
- Stock Symbol
-
QGEN
- Investments
-
59
- Share Price
-
$49.39
- (As of Thursday Closing)
Qiagen General Information
Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
Contact Information
Website
www.qiagen.com
Formerly Known As
Diagen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Stock Exchange
NYS
Primary Office
- Qiagen Strasse 1
- 40724 Hilden
- Germany
+49 02103 000
Qiagen Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $49.39 | $49.44 | $40.38 - $51.30 | $11.3B | 228M | 754K | $2.04 |
Qiagen Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 10,023,767 | 13,618,310 | 13,375,487 | 8,720,977 |
| Revenue | 2,225,932 | 2,251,657 | 1,870,346 | 1,526,424 |
| EBITDA | 813,831 | 885,686 | 705,771 | 205,754 |
| Net Income | 463,553 | 512,599 | 359,188 | (41,455) |
| Total Assets | 6,516,617 | 6,146,954 | 5,869,619 | 5,235,616 |
| Total Debt | 2,289,246 | 1,963,818 | 1,946,199 | 1,725,091 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Qiagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Qiagen Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
Biotechnology
Hilden, Germany
6,200
As of 2022
00000
000000&0
000000
te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
000000000 00000 (000
Madison, WI
0000
As of 0000
000000000000
000000
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000 000000000
San Diego, CA
00000
As of 0000
00000
0000000000
00000
Add Comparison
Qiagen Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Promega | Formerly PE-Backed | Madison, WI | 0000 | 000000000000 | ||
| 00000000 | Formerly VC-backed | San Diego, CA | 00000 | 00000 | 0000000000 | 00000 |
Qiagen Patents
Qiagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4123653-A1 | Method of evaluating a mutational burden | Pending | 22-Jul-2021 | 000000000 | 0 |
| EP-4099332-A1 | Method for reviewing and manipulating of digital pcr data | Pending | 01-Jun-2021 | 000000000 | 0 |
| US-20220162689-A1 | Method and device for sequencing and detecting dna/rna directly on a sensor | Pending | 23-Nov-2020 | 0000000000 | 0 |
| EP-3971302-A1 | Method for detecting 5-hydroxymethylated cytosine | Pending | 16-Sep-2020 | 0000000000 | |
| US-20220073976-A1 | Cyclone rolling circle amplification, double primer for rolony and repli-rolony and pair-end sequencing process | Pending | 10-Sep-2020 | C12Q1/6806 |
Qiagen Executive Team (54)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Thierry Bernard | Chief Executive Officer, Managing Director & Member of the Executive Committee | ||
| Peer Schatz | Senior Advisor | ||
| Roland Sackers | Chief Financial Officer & Managing Director | ||
| Masae Kawamura | Senior Director, Medical and Scientific Affairs | ||
| Alexandra Koenig | Investor Relations Coordinator |
Qiagen Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Elizabeth Tallett | Self | Board Member | 000 0000 |
| Jonathan Sheldon Ph.D | Qiagen | Senior Vice President, QIAGEN Digital Insights & Member of the Executive Committee | 000 0000 |
| Lawrence Rosen | Qiagen | Chairman of the Supervisory Board & Supervisory Director | 000 0000 |
| Metin Colpan | Qiagen | Co-Founder & Supervisory Director | 000 0000 |
| Thomas Ebeling | Self | Board Member | 000 0000 |
Qiagen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Qiagen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Qiagen Investments & Acquisitions (59)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 09-Jan-2023 | 0000000000 | 00000 | Other Commercial Products | 0000000 0 |
| 00000 | 26-Apr-2022 | 0000000000 | Biotechnology | 000000 00 | |
| 0000000 00000 | 19-Jan-2022 | 00000 | 0000 | Biotechnology | |
| 0000000 00000 | 17-Sep-2020 | 0000000000 | 00000 | Other Healthcare Technology Systems | 0000 0000 |
| Formulatrix (Digital PCR) | 31-Jan-2019 | Corporate Asset Purchase | 00000 | Buildings and Property | 0000 0000 |
Qiagen Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Verogen | Other Commercial Products | San Diego, CA | 2017 |
| 0000000 000000000 | Other Healthcare Technology Systems | Ann Arbor, MI | 0000 |
| 0000000000 | Biotechnology | Beverly, MA | 0000 |
Qiagen ESG
Risk Overview
Risk Rating
Updated January, 31, 2023
15.43 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
0.00
Percentile
Laboratory Equipment and Services
Subindustry
00 of 70
Rank
00.00
Percentile
Qiagen Exits (13)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 | 07-Jan-2019 | 00000 00000 00 | 000.00 | Completed |
|
| 00000000 | 20-Mar-2018 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 0000000000 | 07-Jan-2016 | 00000 00000 00 | 0000 | Completed |
|
| 0000000 0000000000 | 04-Sep-2015 | 00000 0000000 | Completed |
|
|
| Curetis | 24-Nov-2014 | Later Stage VC | 000.00 | Completed |
|